The field of synthetic biology seeks to develop engineering principles for biological systems. Along these lines, synthetic biology can address human metabolic disease through the development of genetic approaches to the study and modification of metabolism. The re-engineering of natural metabolic states provides fundamental understanding of the integrated components underlying dysfunctional metabolism. Alternatively, the development of biological devices that can both sense and affect metabolic states could render unique control over disease states. In this chapter, we discuss the advancement of synthetic biological approaches to monitoring and engineering metabolism, as well as prospects for synthetic biology's future role in the prevention and treatment of metabolic disease.
One goal of synthetic biology is to develop engineering principles and tools for biology. The characterized components of fundamental biological processes provide a platform for uniquely redesigned biological parts and devices, and the processes themselves can be re-engineered for improved or alternative functions. Since the advent of recombinant DNA technology in the 1970s, genes, promoters, and other biological parts have become modularized and rearranged in increasingly complex manners. During the last decade, the development of costeffective DNA sequencing and de novo synthesis has accelerated the generation of new biological parts and bioengineering techniques . As our ability to engineer biological systems increases, so too does our ability to address existing biological problems.
The study and treatment of human disease has benefitted from recombinant DNA and synthetic biology approaches. Disease initiation and progression are strongly linked to impaired pathways of metabolic, regulatory, or protein complexes (Li et al. 2011) . Complex dysfunctions that are not adequately addressed by small-molecule drugs or peptides may be repaired with synthetic biological devices. Correcting aberrant metabolism is arguably the most challenging pathway to address, given the difficulty in monitoring intracellular metabolites. Biological devices that sense and respond to metabolism may be better equipped to correct metabolism at the cellular scale. Within this chapter, the terms dysfunctional metabolism and metabolic disease generally describe any disorder characterized by metabolic dysregulation. This includes diabetes, obesity, cancer, cardiovascular disease, Alzheimer disease, and Crohn disease (Suhre et al. 2011) .
Whereas some of these metabolic diseases are due to the altered or missing function of a single gene, many are complex polygenic disorders that have proven difficult to cure (Newgard 1992) . The initial promise of recombinant DNA technology to cure genetic disorders has not been completely realized (Newgard 1992) . It was quickly discovered that greater understanding of existing metabolic pathways and their dysfunction is fundamental to improving disease treatment, including diseases stemming from a single affected gene. The accumulation of metabolic pathway knowledge and model-based evaluation of dysfunction has facilitated our ability to engineer natural metabolism. These advancements, combined with improved gene synthesis and gene-transfer technologies, have also permitted the construction of synthetic devices that can sense and affect metabolism (for review, see Weber and Fussenegger 2009) . In this chapter, we discuss both the engineering of natural metabolism and the construction of synthetic devices for metabolism and show how these two approaches have established synthetic biology as a valuable tool against metabolic disease.
A challenge in metabolic engineering is that control of metabolic flux is often distributed throughout a pathway, rather than a single enzyme serving as a rate-limiting step (Thomas and Fell 1996; Fell 1997) . Consequently, engineered pathways must typically be tuned to maximize throughput, often by adjustment of enzyme concentrations (Dekel and Alon 2005; Boyle and Silver 2009; Wang et al. 2009 ). Multisite control is likely to be a property of biological devices that reroute metabolic flux in the human body. To achieve quantitative control over metabolism, a wide array of biological control elements, such as promoters, ribosome-binding sites, and riboswitches, have been repurposed or synthesized . The efficacy and robustness of control elements are especially critical in a therapeutic context, as compared with traditional metabolic engineering. Microbes are often engineered to simply act as pipes for chemical conversions, tuned to continuously produce a target compound. In contrast, biological devices destined for the human body will require stringent logic and control. For example, bacteria that target tumors for destruction must distinguish between normal and cancerous tissue, to avoid destroying healthy cells (Anderson et al. 2007) .
Achieving an appropriately strict regulation of metabolic networks requires a quantitative understanding of network properties. Models of microbial metabolism have been instrumental to many metabolic engineering efforts (Burgard et al. 2003; Pharkya et al. 2004; Bro et al. 2006; Kennedy et al. 2009; Wintermute and Silver 2010) . In the context of human biology, models are important tools in analyzing metabolomic data, predicting drug behavior, and identifying metabolic flux modes that characterize disease. Because the assistive tools of mutagenesis and selection are not available for human systems, models are vital to understanding human metabolism.
Modeling frameworks such as Flux Balance Analysis (FBA) and its derivatives have been instrumental in the engineering of microbial metabolism (Varma and Palsson 1994; Boyle and Silver 2009; Gianchandani et al. 2010) . FBA-type models take advantage of our nearcomprehensive understanding of the stoichiometry of metabolic networks across many species. In essence, these models incorporate all known metabolic reactions in an organism and identify a steady-state flux distribution that maximizes or minimizes a user-defined objective function (Feist and Palsson 2010) . To increase their biologic relevance and minimize the number of optimal flux distributions, FBA-type models further incorporate constraints such as limits on nutrient-uptake rate. The details on the formulation, selection of constraints and objective functions, optimization strategies, and practical applications of these models have been extensively reviewed ( Fig. 1) (Varma and Palsson 1994; Edwards et al. 2002; Oberhardt et al. 2009; Terzer et al. 2009) . In this chapter, we present progress in the adaptation of these models to mammalian systems.
Mammalian biology is inherently more complex than that of bacteria or yeast. Models of mammalian tissues, tumors, or cell lines must integrate constraints on gene expression and multicellular interactions that are representative of a given tissue type. These parameters are often inferred from microarray datasets, starting with a generic model of human metabolism and removing unexpressed enzymes (Duarte et al. 2007; Jerby et al. 2010) . Cell-specific extracellular metabolite availability and objective functions improve model accuracy. The relatively low-parameter requirements of FBA-type models also allows multicellular metabolic interactions to be modeled (Stolyar et al. 2007; Wintermute and Silver 2010) .
Most problematic for constraint-based approaches is the formulation of appropriate objective functions for mammalian cells. When modeling microbes, it is commonly assumed that laboratory-adapted strains such as Escherichia coli are tuned for rapid growth (Ibarra et al. 2002) . In contrast, many cells in the human body are not constantly dividing (Berk 2005) . Even proliferative cancer cells are likely to be governed by more complex objectives than rapid growth. Rather than defining an objective function a priori, many researchers have instead opted to infer the wild-type flux distribution from transcriptomic and proteomic data (Shlomi et al. 2008; Jerby et al. 2010; Lewis et al. 2010) .
A multitissue model of brain metabolism was recently constructed to study Alzheimer disease ( Fig. 1) (Lewis et al. 2010) . Multiple "omics" datasets guided construction of metabolic networks relevant to each modeled cell type: astrocytes, glutamatergic neurons, GABAergic neurons, and cholinergic neurons. Relevant extracellular metabolic reactions such as those related to the endothelium, blood supply, and the interstitial spaces between cells were also included.
Because gene deletion simulations are a common application of constraint-based approaches, these models of neuron metabolism were used to simulate enzyme deficiencies common to Alzheimer disease, such as decreased mitochondrial pyruvate dehydrogenase activity (Bubber et al. 2005; Lewis et al. 2010 ). This simulation is achieved by removing a network reaction and recalculating the flux distribution of the mutant network (Segrè et al. 2002; Burgard et al. 2003; Duarte et al. 2004; Kennedy et al. 2009; Rocha et al. 2010) . In lieu of an objective function for brain energy metabolism, researchers instead used Monte Carlo sampling to identify feasible flux distributions (Lewis et al. 2010) . These simulations provided mechanistic insight into the expression changes observed in microarray datasets, including the identification of neuronal pathways that may limit synthesis of acetyl-CoA and, by extension, the neurotransmitter acetylcholine in Alzheimer neurons.
Network-scale models of metabolism may be instrumental in the analysis of complex metabolic dysfunction. For example, cancer genome studies have revealed that cancer cells often contain multiple gene-copy-number changes and mutations (Beroukhim et al. 2010) . Evidence of multisite control in cancer metabolism suggests that several enzymes must be modulated to correct or halt metabolism in cancer cells (Rasnick and Duesberg 1999; Moreno-Sánchez et al. 2010; Schrattenholz et al. 2010 ). Metabolic models that can integrate omics data will be useful in diagnosing and identifying therapeutic strategies. As in the Alzheimer disease example, inferring metabolic objective functions of cancer cells will identify metabolic pathways to be targeted for modulation with drugs or synthetic devices.
SYNTHETIC DEVICES FOR METABOLIC DYSFUNCTION
Given a quantitative understanding of metabolic dysfunction, we must then be able to correct these dysfunctions in a predictable manner. Engineered biological pathways termed synthetic circuits or devices may be designed to execute useful functions within single living human cells. Synthetic circuits offer a more controlled approach to traditional drug and gene therapies, such as the ability to dynamically silence, activate, and tune the expression of desired genes and drugs (Khalil and Collins 2010) . Simply put, synthetic devices detect an environmental signal (e.g., hypoxia) that is processed by a genetic logic circuit, which filters the signal and activates a cellular response (e.g., drug delivery) (Fig. 2) . Such circuits can communicate a cell's metabolic state and provide a therapeutic biological action. Organisms ranging from bacteria to mammalian cells provide an abundance of existing modular sensory regulatory circuits, the components of which can be transferred to synthetic circuits in human cells. Using cues from nature, synthetic circuits have been designed to regulate cells at the transcriptional, translational, or posttranslational level for the purpose of studying and treating metabolic disease.
TRANSCRIPTIONAL REGULATION
One way that cells mobilize a response to metabolic perturbations is via transcription. In simple terms, an input signal modulates the binding of transcription factor proteins at binding sites near promoters, conferring a gene activity state. Following this design, synthetic circuits have been engineered with endogenous or artificial transcription factors fused to activators or repressors that bind natural or synthetic elements within a minimal promoter to control gene output. Sensitivity and specificity can be introduced to this synthetic system by various methods (for review, Burrill and Silver 2010): adding, subtracting, or mutating binding sites; using activators and repressors of varying strengths; or inserting intronic sequences in promoter regions to tune transcriptional Tissue-specific constraint-based models start with a genome-scale metabolic network. These networks, such as Homo sapiens build 1 (Duarte et al. 2007 ; http://gcrg.ucsd.edu/Organisms), contain all possible metabolic reactions defined in the human genome. Tissue-specific datasets, such as expression microarrays, are then used to define the particular subset of reactions that occurs in a given tissue. This reduced network is then used to model the tissue of interest. (B) A visualization of constraint-based modeling. Constraints on metabolic fluxes, input rates, and output rates define the bounds of the feasible flux space for a given metabolic network. To determine which flux mode is most likely to exist in the tissue to be modeled, an objective function is chosen, which defines the metabolic flux that the system seeks to optimize. Although many solution algorithms exist, most involve the intersection of the objective function with the surface of the feasible flux space. (C ) Compartmentalization of a human brain metabolic model (Lewis et al. 2010) . Cell-specific models were defined for astrocytes, glutamatergic neurons, GABAergic neurons, and cholinergic neurons. Metabolic networks for the endothelium, blood, and interstitial space (int) connected the cell-specific metabolic networks. Mitochondria (mito) for each cell type were also modeled as discrete metabolic compartments within each cell type. Exchange fluxes, the input and output rates of metabolites, were experimentally measured and used to fine-tune the model. (Deans et al. 2007 ). In the on state, IPTG binds to LacI repressor proteins (orange), thus freeing lac operator (LacO) sites and permitting EGFP and TetR transcription. TetR proteins (yellow) further enhance EGFP expression by binding to a tet operator (TetO) site located upstream of the RNAi module ( pink), thus repressing short hairpin RNA (shRNA) transcription. In the off state, LacI repressor proteins are constitutively expressed and bind to LacO sites in the transgene, thereby repressing EGFP expression. LacI repressor proteins also bind to LacO sites in TetR, causing TetR repression. Thus, shRNA is transcribed and silences EGFP. (D) Synthetic cell-type detector (Xie et al. 2011) . Using markers characteristic of HeLa cancer cells, a sensor motif for markers expressed high and low was engineered. The HeLa-high motif is comprised of a double-inversion module (R1 and R2) that allows expression only if the marker is present at or above its level in HeLa but represses the output if the marker is low. A HeLa-low marker sensor was implemented by fusing repeats of complementary target sites into the output's 3 0 -UTR. Multiple sensors were combined by fusing their corresponding microRNA (miRNA) targets in the output's 3 0 -UTR. If expression levels match that of HeLa cells, the proapoptotic protein hBax is activated. (E) Synthetic signaling cascade (Ye et al. 2011 ). Blue-light-mediated photoisomerization of the retinal chromophore triggers melanopsin conformational changes that activate the Gaq-type G protein (Gaq), phospholipase C (PLC), and phosphokinase C (PKC). Consequently, calcium ion influx occurs via transient receptor potential channels (TRPCs), ultimately resulting in activation of the transcription factor, nuclear factor of activated T cells (NFAT), and induction of NFAT-inducible transgenes.
rates . The primary motivation in the design of these control elements is to ensure that a synthetic circuit behaves in a predictable, controlled manner, which is critical when translating such devices to human studies.
Several systems have been designed in which a signalresponsive transcription factor is fused to a DNA-binding domain that binds to an engineered promoter upstream of a reporter gene. This design has been used to report on hormone concentrations (Braselmann et al. 1993) , hypoxia (Tang et al. 2005) , redox levels (Weber et al. 2006) , and chromatin modifications (Hansen et al. 2008 ). In recent work by Haynes et al. (Haynes and Silver 2011) , Polycomb chromatin protein was used to engineer artificial transcription factors that recognize repressive histone methylation marks and activate silenced, disease-related genes in human cancer cells (Fig. 2A) . In other examples, custom-built transcription factors composed of zinc-finger DNA-binding domains respond to external stimuli by targeting specific mammalian genes. Endogenous genes that are silenced in many cancers-such as the antiangiogenic pigment epithelium derived factor (Yokoi et al. 2007 ) and the breast tumor suppressor maspin (Beltran et al. 2007 )-have been reactivated in mammalian cell culture using this method.
Other transcription-based biosensors employ minimal promoters with natural regulatory DNA elements that are activated by environment-responsive, endogenous transcription factors, producing sensors capable of reporting the presence of progesterone (Strähle et al. 1987) , DNA damage (Ohno et al. 2008) , and glucocorticoid hormone (Meijsing et al. 2009 ). Circuits such as those described are capable of providing valuable information about the internal metabolic environment. This information can then be potentially used for restoring misregulated metabolism in a therapeutic setting. Furthermore, the described devices are highly modular, making them amenable to the study of multiple diseases.
In some cases, it might be desirable to use a synthetic circuit that controls transcription by processing more complex input logic. Examples include memory circuits and oscillators, both of which naturally mediate gene expression to control metabolism, signaling pathways, and cell differentiation. Biological memory can be defined as a sustained cellular response to a transient stimulus (Burrill and Silver 2011) . One way that cells accomplish this task is through bistable transcriptional states, such that a chemical state becomes defined as on or off in response to environmental input and, given certain parameters, can be inherited through DNA replication and cell division. Synthetic memory circuits modeled from this design are capable of sensing external inputs and producing permanent expression of a reporter (e.g., fluorescent protein, specific gene, or drug). Two have been recently designed in yeast-both use transcriptional positive feedback to convert a transient exposure to galactose (Ajo-Franklin et al. 2007) or DNA damage (Burrill and Silver 2011) into sustained expression of a fluorescent reporter (Fig. 2B) . If transferred to mammalian systems, memory devices such as these could be used to study the long-term effects of particular stimuli on a cell population or provide long-term gene or drug dosage in response to transient inputs.
Synthetic mammalian oscillators based on their natural counterparts can control the periodic expression of desired genes for therapeutic reasons. Indeed, most hormones are released in time-dependent pulses, and replicating these patterns in hormone dosage to patients may decrease side effects and improve response (Khalil and Collins 2010) . One circuit that could be used for such a purpose is the sense -antisense transcriptional device engineered by Tigges et al. (2009) . The device encodes a positive and a time-delayed negative-feedback loop that enables self-sustained oscillatory mammalian gene expression. The work shows that oscillation frequency, amplitude, and damping rates can be tuned by adding regulatory elements (e.g., repressors, activators) responsive to artificial chemical inputs or by altering the network topology. Another engineered oscillator allows for pulses of gene expression via negative feedback. The pulses can vary in transcription time by using increasingly long introns to lengthen the time required for gene transcription . Such a device could be used to tightly regulate synthetic gene expression in mammalian systems.
A final example of a more complex transcription regulator is a synthetic genetic counter (Friedland et al. 2009 ). Control over drug release might be integrated by programming a synthetic system to self-destruct after a specific number of gene or drug release pulses or cell cycles. Many of these transcriptional tools to control drug and gene delivery have yet to be successfully engineered in human cells, but their development in bacteria and yeast is laying the groundwork for future translational applications.
TRANSLATIONAL REGULATION
RNA molecules are an attractive target for bioengineering owing to their many functional capacities. These functions include splicing RNA, catalyzing biochemical reactions, and regulating gene expression (Khalil and Collins 2010) . Synthetic biologists have used RNA to achieve direct and tight regulation of protein concentrations primarily via RNA interference (RNAi) and functional RNAs (ribozymes, riboswitches) (Haynes and Silver 2009).
RNAi uses sequence complementarity to silence target messenger RNA (mRNA). As such, RNAi constructs can be designed against any desired RNA. Bioengineers have used RNAi to tighten control and tweak the expression dynamics of synthetic systems. Greber et al. (2008) demonstrated that intronic short interfering RNAs (siRNAs) can reduce basal gene expression of inducible transcription systems (Greber et al. 2008) . Deans et al. (2007) designed an inducible switch in mammalian cells that produces shRNAs to prevent leaky expression of transgenes (Fig. 2C) .
Other synthetic devices use functional RNAs to control circuit behavior (Bayer and Smolke 2005; Beisel et al. 2008 ). Ribozymes, antiswitches, and shRNA switches contain an aptamer domain (sensor) involved in specific ligand recognition and an expression platform that controls gene activity by causing mRNA conformational changes (Mulhbacher et al. 2010) . The flexibility and ease of design of synthetic aptamer domains for a wide range of target ligands makes them a valuable synthetic biology tool (Win and Smolke 2009 ). Ribozymes can specifically cleave target RNA and have been effectively used in gene therapy for cancer and other diseases (Win and Smolke 2008; Culler et al. 2010; Mulhbacher et al. 2010) . For example, a hammerhead ribozyme targeting the human epidermal growth factor receptor HER-2 reversed the malignant phenotype of breast cancer cells (He et al. 2010) . Metabolite-binding riboswitches also represent a novel solution to sensing and studying metabolic disease. To date, synthetic riboswitches have been built to sense thiamine pyrophosphate, lysine, flavin mononucleotide, and guanine (Mulhbacher et al. 2010) . The pairing of switchable aptamer domains with ribozymes that degrade an mRNA in a ligand-dependent manner allows a rapid regulatory response to changes in intracellular metabolite concentrations (Win and Smolke 2008) . The construction of aptamer domains responsive to other environmental conditions or metabolites could serve as future therapeutic and research tools for disease.
Other RNAi-based synthetic devices can process multiple inputs, making it possible to specifically detect diseases characterized by several metabolic signals. A mammalian logic evaluator composed of genes containing multiple synthetic RNAi target sequences was shown to correctly detect up to five siRNA inputs (Rinaudo et al. 2007 ). In a recent paper, Xie et al. (2011) showed that expression of endogeneous miRNAs characteristic of cervical cancer cells could trigger apoptosis via a synthetic transcriptional device regulating expression of human Bcl-2-associated X protein hBax (Fig. 2D ). Circuits such as these are useful in situations where a single metabolic signal does not define an environment. The continued engineering of logic circuits that evaluate endogenous cellular inputs will lead the way to synthetic devices that can sense and correctly respond to complex physiological conditions.
CELL-SIGNALING REGULATION
At the posttranslational level, signal transduction pathways represent another platform for synthetic regulation of human cells. Cell-signaling pathways are often misregulated in metabolic diseases and are thus a target for therapeutic intervention. The sensor element for many signaling pathways is a membrane-bound or nuclear protein receptor. Whereas environment-responsive promoters and RNA aptamers are derived from nature or selections, protein receptors can be designed at the level of molecular interaction (Khalil and Collins 2010) . Existing signaling pathways provide many further components that can be harnessed to build tunable, sensitive, and specific synthetic pathways, such as the number and spacing of proteins in a given cascade. Thus, signal transduction pathways constitute a modular method for programming protein-based regulators.
The construction of chimeric protein ligands that bind receptors in a precise and predictable manner can increase the specificity of synthetic devices for target cell types. For example, a chimera was designed to specifically bind to cells with both epidermal growth factor (EGF) receptor and interferona-2a (IFNa-2a) receptor (Cironi et al. 2008 ). These authors demonstrated that a series of IFNa-2a mutations could progressively decrease the on rate and dissociation constant of the IFNa-2a-IFNa receptor 2 (IFNAR2) interaction (Cironi et al. 2008 ). This quantitative knowledge was then applied to the design of chimeras in which IFNa receptor activation depends on the presence of EGF receptor on the same cell. This work illustrates the value of a quantitative approach to tool design and suggests useful techniques for modulating protein -protein interactions.
A number of synthetic approaches have addressed the abnormal cell signaling associated with diabetes mellitus. Diabetes develops when insulin is inadequately produced by the pancreas or not effectively used by cells, resulting in the failure of glucose absorption from blood for cellular energy. It has been argued that cell-based treatments for insulin-dependent diabetes may provide more physiologic regulation of blood glucose levels than daily insulin injections (Zhang et al. 2008) . Surrogate b cells have been developed to synthesize functional insulin in response to changing glucose levels, thus re-establishing a normal metabolic signaling pathway. This was accomplished both in human cell culture (Bara and Sambanis 2008) and mouse models (Zhang et al. 2008 ), the latter revealing that blood glucose levels could be reduced to normal using this method. These studies suggest that the use of genetically engineered cells to express human insulin might be a powerful therapeutic approach to diabetes treatment.
Other synthetic approaches to diabetic regulation have involved inserting entirely new signaling pathways into human cells and mice. In one example, the investigators designed a light-inducible signaling cascade to control transgene expression of the glucagon-like peptide 1, a protein that increases insulin secretion. The implantation of the device in diabetic mice coincided with the dissipation of glycemic excursions (Fig. 2E) (Ye et al. 2011) . In another system, the glyoxylate shunt pathway was introduced to mammalian liver cells and mice (Dean et al. 2009 ). Mice expressing the shunt exhibited increased fatty-acid oxidation and decreased tendencies toward diet-induced obesity. This work offers new synthetic tools for studying and manipulating biological networks to correct metabolic disorders.
TOOL DELIVERY
Decades of experience in molecular genetics and gene therapy have demonstrated the importance of caution when designing novel genetic therapeutics (Denèfle 2011) . In developing therapeutic synthetic devices for human cells, it is important to anticipate deleterious off-target effects and host-cell interactions. In cases where engineered human cells need to be delivered to the human body, the cells will probably need to be implanted (Ausländer et al. 2011) . To prevent immune system rejection of nonautologous cells and the side effects of immunosuppressive drugs, one might want to encapsulate engineered cells in a biocompatible, semipermeable membrane. This technology has been limited so far by inadequate nutrient transport and undesirable immune responses (Ausländer et al. 2011) . Recent efforts have focused on developing submicron scale coatings to reduce cell mass and incorporating anti-inflammatory capabilities into synthetic membranes (Ausländer et al. 2011) . This area of work will have to carefully but continually improve to actualize the potential of cell-based therapeutics.
Delivery methods and efficacy will also depend on the cell type to be engineered. Immortalized cancer cell lines common to laboratory research are unlikely to be utilized in human therapies. Engineered stem cells, however, are more stable and predictable to engineer and have already been used safely in several clinical trials (Denèfle 2011; Trounson et al. 2011) . In particular, mesenchymal stem cells (MSCs) possess many advantageous cellular characteristics, such as ease of isolation, high expansion potential, and genetic stability. For these reasons, MSCs are popular therapeutic and engineering platform candidates (Le Blanc and Ringdén 2007) .
An alternative to engineering human cells is to design synthetic microbial devices that interact with human cells. Several factors make the prospect of synthetic microbial therapeutics more likely in the near term than devices that modify mammalian cells. Microbial engineering is generally easier because microbes have smaller genomes, grow faster, and are more genetically accessible than mammalian cells (Weber and Fussenegger 2009) . Furthermore, microbial treatments are likely to be more transient than genetherapy-type approaches, rendering them potentially safer. Whereas the mislocalization of microbes in the human body can itself cause disease, the human body is home to trillions of symbiotic microbes; engineering these species in their respective niches may be a successful strategy.
For example, synthetic microbial devices might be used in the selective destruction of cancer cells, therein providing the benefits of traditional chemotherapy without the negative side effects (Anderson et al. 2006 (Anderson et al. , 2007 Cironi et al. 2008) . To this end, cancer-targeting bacteria have been developed in which their ability to invade and kill cancer cells is linked to environmental signals that are specific to the tumor microenvironment (such as hypoxia and bacterial aggregation). At the center of this device is a modular AND gate that triggers cell invasion only if the two inputs are detected (Anderson et al. 2006 ). This system is composed of modular parts, such that the system is adaptable to different cancer types. Recently, nonpathogenic or immunogenic photosynthetic bacteria were engineered with invasin and listeriolysin to invade the cytoplasm of mammalian cells (Agapakis et al. 2011) . This work presents the possibility of using photosynthetic bacteria as a novel chassis for synthetic devices in human systems.
It should be noted that the safe delivery of both mentioned bacterial devices to patients may be problematic, because an immune response against engineered bacteria would be highly undesirable. The human gut is a likely target for engineered bacteria. The average person harbors approximately 160 bacterial species in his or her gut, with about 10 14 individual microbial cells (Qin et al. 2010; Tilg and Kaser 2011) . The variety of species found in a single person can depend on the person's location, diet, and disease state, among other factors. Cross talk between the host and the microbiome is also implicated in disease risk and progression, including obesity, cardiovascular disease, diabetes, cancer, Crohn's disease, ulcerative colitis, and the metabolic syndrome (Martins Dos Santos et al. 2010; Tilg and Kaser 2011) . There is tremendous potential for engineered microbes to observe, diagnose, and potentially treat these diseases.
The species composition (and therefore the metabolic state) of the gut microbiome is maintained through intercellular communication, both between the host and the microbiome and within the microbiome itself. Ideally, engineered microbes in the gut will participate in this communication to maintain homeostasis. Two signaling peptides, glucagon-like peptide 1 (GLP-1) and pancreatic and duodenal homeobox gene 1 (PDX-1), have been demonstrated to induce insulin synthesis in the intestinal epithelium (Yoshida et al. 2002; Suzuki et al. 2003) . E. coli engineered to secrete GLP-1 and PDX-1 in response to glucose were demonstrated to trigger insulin production in Caco-2 cells (Duan et al. 2008) . Introduction of this device into the gut of diabetic patients could restore glucose-dependent insulin production. A similar device, this time secreting Vibrio cholerae quorum-sensing molecules, was capable of preventing V. cholerae propagation in mice (Duan and March 2010) . Prophylactic engineered bacteria have also shown promise in preventing HIV infection of the cervicovaginal mucosa (Rao et al. 2005; Liu et al. 2006; Yu et al. 2009; Duan and March 2010; Lagenaur et al. 2011) .
Fecal transplantation is emerging as a clinical treatment for gastrointestinal infections, particularly for Clostridium dificile (Palmer 2011; Tilg and Kaser 2011) . The primary benefit of fecal transplantation is the recolonization of the gastrointestinal tract by commensal microbes that were eradicated during the treatment of the initial infection. The introduction of engineered bacteria to the gastrointestinal tract may prevent infection altogether. Beyond the use of natural probiotic bacteria, or the constitutive secretion of recombinant peptides by engineered bacteria, we envision that bacteria equipped with synthetic gene circuits might sense unwanted changes in the body and react by secreting drugs or signaling molecules. This secondary immune system could augment the body's natural defenses to fight disease at preclinical stages.
CONCLUSIONS AND OUTLOOK
In this chapter, we have provided an overview of the synthetic biology tools available for human disease and metabolism. Whereas some of these techniques have been successfully applied to human patients, many synthetic biology tools remain at the laboratory bench. Successful transition to the clinic will require the development of robust delivery methods and significant improvement in device reliability and specificity. These objectives are in line with the ultimate goals of synthetic biology-to build biological systems with defined and predictable functions. Ultimately, smart synthetic devices, which target themselves to the correct tissues and regulate their own dosage, may be safer and more effective than current therapeutics.
We have touched upon existing and proposed methods for introducing synthetic tools to the human body. To date, synthetic biologists have constructed a diverse array of components that may contribute to future therapeutics, but assembly of a complete device that is ready for human testing has yet to be realized. Therapeutic implantation of synthetic biological devices is but one application of these tools; synthetic biological devices have already enhanced our understanding of disease and metabolism.
The maturation of synthetic biology in the medical arena is dependent on further scientific and regulatory development. To be considered for clinical trials, the reliability and accuracy of synthetic devices must be increased. The limited number of animal experiments conducted thus far (Duan and March 2010; Lagenaur et al. 2011; Ye et al. 2011) speaks to the infancy of the field. The complexity of engineered mammalian devices has tended to lag behind progress in the synthetic biology of simpler systems. The modularization of genetic circuits, that is, repurposing and combining devices to produce new functions or operate in different cell types, has been difficult. Our own experience with memory devices (and the experience of others with logic gates) has taught us that devices can be modularized, but that more than a simple promoter swap is often necessary (Ajo-Franklin et al. 2007; Anderson et al. 2007; Burrill and Silver 2011) . These issues are not insurmountable, but they do lengthen the time horizon for building clinical-grade devices. Navigating the complex pharmaceutical regulatory landscape will present an entirely different yet arduous challenge. These issues raise the importance of accelerating the mammalian engineering design cycle: We must expand work in therapeutically relevant cell lines, incorporate improved models of device function, and better integrate with the related fields of stem cell therapy and tissue engineering.
The stakes for human applications of synthetic biology are higher than for applications confined to bioreactors. In developing synthetic biology tools for human health, we must continually consider the relevant ethical and social issues surrounding this research (Yearley 2009 ). Taking initiative in these areas will be essential to the responsible development of synthetic biological therapeutics. Recent experience in the development of experimental therapies has underscored the importance of caution in developing human trials (Marshall 1999; Gabardi et al. 2011) . Balancing risks with the transformative potential benefits of synthetic biology will be a continual and necessary challenge as synthetic biology enters the clinic.
